Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer
Authors
Keywords
-
Journal
PROSTATE
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-01-20
DOI
10.1002/pros.24104
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
- (2020) Justin Ferdinandus et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Pilot Study of Hyperfractionated Dosing of Lutetium‐177–Labeled Antiprostate‐Specific Membrane Antigen Monoclonal Antibody J591 ( 177 Lu‐J591) for Metastatic Castration‐Resistant Prostate Cancer
- (2020) Muhammad Junaid Niaz et al. ONCOLOGIST
- TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).
- (2020) Michael S Hofman et al. JOURNAL OF CLINICAL ONCOLOGY
- 111In-pentetreotide scintigraphy vs. 68Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden
- (2019) Thomas A. Hope et al. JOURNAL OF NUCLEAR MEDICINE
- 68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
- (2019) Alexander Heinzel et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.
- (2019) Jeremie Calais et al. JOURNAL OF CLINICAL ONCOLOGY
- PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy
- (2019) Hans-Jürgen Wester et al. SEMINARS IN NUCLEAR MEDICINE
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
- (2019) Alec Paschalis et al. EUROPEAN UROLOGY
- 68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
- (2019) Jonathan Damjanovic et al. CANCER IMAGING
- TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
- (2019) Michael S. Hofman et al. BJU INTERNATIONAL
- Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer
- (2019) John Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Response prediction of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH.
- (2019) Hendrik Rathke et al. JOURNAL OF NUCLEAR MEDICINE
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Results of a prospective phase 2 pilot trial of Lu177 PSMA 617 therapy for metastatic castrate resistant prostate cancer including Imaging predictors of treatment response and patterns of progression.
- (2018) Louise Emmett et al. Clinical Genitourinary Cancer
- Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes
- (2018) John A Violet et al. JOURNAL OF NUCLEAR MEDICINE
- Dose Deposits from 90Y, 177Lu, 111In, and 161Tb in Micrometastases of Various Sizes: Implications for Radiopharmaceutical Therapy
- (2016) E. Hindie et al. JOURNAL OF NUCLEAR MEDICINE
- Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
- (2015) Neeta Pandit-Taskar et al. EJNMMI Research
- Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
- (2014) Susan Halabi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
- (2013) S. T. Tagawa et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started